Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Rana Mckay

    TitleAssistant Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0987
    CA La Jolla 92093
    Phone858-822-6185
    vCardDownload vCard

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Hamieh L, McKay RR, Lin X, Simantov R, Choueiri TK. Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database. Clin Genitourin Cancer. 2017 Aug 12. PMID: 28918175.
        View in: PubMed
      2. Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, Campbell SC, Rini BI, Derweesh IH. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol. 2017 Aug 09. PMID: 28802883.
        View in: PubMed
      3. Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311. PMID: 28762529.
        View in: PubMed
      4. Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2017 May 31. PMID: 28645482.
        View in: PubMed
      5. de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Mar 21. PMID: 28410911.
        View in: PubMed
      6. Jay R, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503. Urol Oncol. 2017 Mar; 35(3):117-118. PMID: 28159495.
        View in: PubMed
      7. McKay RR, Werner L, Fiorillo M, Roberts J, Heath EI, Bubley GJ, Montgomery RB, Taplin ME. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Aug; 15(4):463-471. PMID: 27890446.
        View in: PubMed
      8. McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):935-945. PMID: 27683182.
        View in: PubMed
      9. Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol. 2016 Sep 06. PMID: 27601543.
        View in: PubMed
      10. McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME. Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 Apr; 15(2):e289-e298. PMID: 27651103.
        View in: PubMed
      11. McKay RR, Werner L, Fiorillo M, Nakabayashi M, Kantoff PW, Taplin ME. Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2016 Dec; 19(4):398-405. PMID: 27502737.
        View in: PubMed
      12. Pernar CH, Markt SC, McKay RR, Mucci LA. CHALLENGE Trial 1 Year Feasibility Results-Letter. Cancer Epidemiol Biomarkers Prev. 2016 Aug; 25(8):1277. PMID: 27418272; PMCID: PMC4970942 [Available on 08/01/17].
      13. Hamieh L, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2017 Apr; 15(2):221-229. PMID: 27460432.
        View in: PubMed
      14. McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98. PMID: 27198170.
        View in: PubMed
      15. Marmarelis ME, Davis MR, Sethi NS, Krajewksi KM, McKay RR, Choueiri TK, Ott PA. Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. J Immunother Cancer. 2016; 4:26. PMID: 27099755; PMCID: PMC4837591.
      16. McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol. 2016 Jun 1; 34(16):1913-20. PMID: 27044933.
        View in: PubMed
      17. Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 Aug; 14(4):e299-305. PMID: 26778006.
        View in: PubMed
      18. McKay RR, Lin X, Albiges L, Fay AP, Kaymakcalan MD, Mickey SS, Ghoroghchian PP, Bhatt RS, Kaffenberger SD, Simantov R, Choueiri TK, Heng DY. Statins and survival outcomes in patients with metastatic renal cell carcinoma. Eur J Cancer. 2016 Jan; 52:155-62. PMID: 26687834.
        View in: PubMed
      19. Albiges L, Fay AP, McKay RR, Kaymakcalan MD, Choueiri TK. Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective. Surg Pathol Clin. 2015 Dec; 8(4):657-62. PMID: 26612219.
        View in: PubMed
      20. Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 2016 Feb 01; 122(3):411-9. PMID: 26540173.
        View in: PubMed
      21. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 01; 121(19):3435-43. PMID: 26058385.
        View in: PubMed
      22. McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 2015 Aug 01; 121(15):2603-11. PMID: 25903013; PMCID: PMC4566852.
      23. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2471-9. PMID: 25724518; PMCID: PMC4566854.
      24. Fay AP, Signoretti S, Callea M, Tel? GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3. PMID: 25767716; PMCID: PMC4357210.
      25. Sammon JD, McKay RR, Kim SP, Sood A, Sukumar S, Hayn MH, Hu JC, Kibel AS, Nguyen PL, Peabody JO, Saad F, Sun M, Varda B, Menon M, Choueiri TK, Trinh QD. Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology. 2015 Feb; 85(2):343-9. PMID: 25623683.
        View in: PubMed
      26. Sun T, McKay R, Lee GS, Kantoff P. The role of miRNAs in prostate cancer. Eur Urol. 2015 Oct; 68(4):589-90. PMID: 25577717.
        View in: PubMed
      27. Grünwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May; 67(5):952-8. PMID: 25577718; PMCID: PMC4570832.
      28. McKay RR, Mamlouk K, Montgomery B, Taplin ME. Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report. Clin Genitourin Cancer. 2015 Aug; 13(4):e325-8. PMID: 25600761; PMCID: PMC4563804.
      29. Roghmann F, Antczak C, McKay RR, Choueiri T, Hu JC, Kibel AS, Kim SP, Kowalczyk KJ, Menon M, Nguyen PL, Saad F, Sammon JD, Schmid M, Sukumar S, Sun M, Noldus J, Trinh QD. The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015 Jan; 33(1):17.e9-17.e18. PMID: 25443265.
        View in: PubMed
      30. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015 Jan 15; 121(2):311-9. PMID: 25236375; PMCID: PMC4293233.
      31. Ravi P, Karakiewicz PI, Roghmann F, Gandaglia G, Choueiri TK, Menon M, McKay RR, Nguyen PL, Sammon JD, Sukumar S, Varda B, Chang SL, Kibel AS, Sun M, Trinh QD. Mental health outcomes in elderly men with prostate cancer. Urol Oncol. 2014 Nov; 32(8):1333-40. PMID: 25153773.
        View in: PubMed
      32. McKay RR, Zukotynski KA, Werner L, Voznesensky O, Wu JS, Smith SE, Jiang Z, Melnick K, Yuan X, Kantoff PW, Montgomery B, Balk SP, Taplin ME. Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):325-31. PMID: 25091040; PMCID: PMC4566855.
      33. Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK. Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov; 92(2):123-32. PMID: 24958272; PMCID: PMC4578298.
      34. McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol. 2014 Sep; 66(3):502-9. PMID: 24613250; PMCID: PMC4145043.
      35. Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014 May; 113(5b):E67-74. PMID: 24053727; PMCID: PMC4117702.
      36. Fennessy FM, McKay RR, Beard CJ, Taplin ME, Tempany CM. Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol. 2014 Feb; 7(1):120-9. PMID: 24772215; PMCID: PMC3998683.
      37. McKay RR, Taplin ME, Choueiri TK. Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. Hematol Oncol Clin North Am. 2013 Dec; 27(6):1261-83, ix. PMID: 24188262; PMCID: PMC4127574.
      38. McKay RR, Choueiri TK, Taplin ME. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs. 2013 Sep; 73(13):1417-30. PMID: 23943203; PMCID: PMC4127573.
      39. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014 Mar; 65(3):577-84. PMID: 23962746; PMCID: PMC4123121.
      40. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw. 2013 Aug; 11 Suppl 3:S1-50; quiz S51. PMID: 23997241.
        View in: PubMed
      41. McKay RR, Kantoff P. Prostate cancer 2012: where do we stand and where are we heading? Oncology (Williston Park). 2012 Dec; 26(12):1222, 1224. PMID: 23413607.
        View in: PubMed
      42. Kim S, McKay RR, Miller K, Shortridge RD. Multiple subtypes of phospholipase C are encoded by the norpA gene of Drosophila melanogaster. J Biol Chem. 1995 Jun 16; 270(24):14376-82. PMID: 7540168.
        View in: PubMed
      43. McKay RR, Chen DM, Miller K, Kim S, Stark WS, Shortridge RD. Phospholipase C rescues visual defect in norpA mutant of Drosophila melanogaster. J Biol Chem. 1995 Jun 02; 270(22):13271-6. PMID: 7768926.
        View in: PubMed
      Rana's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department